Simris Alg conducts directed share issue
The Board of Directors of Simris ALG AB (publ) ("Simris" or the "Company") has today, with the support of authorization from the Annual General Meeting of 25 May 2022, resolved on a directed issue of 3,932,246 shares of series B in connection with the previously communicated and completed acquisition of Cyano Biotech GmbH. Payment will be made through set-off as part payment of the shares in Cyano Biotech GmbH.The reasons for the issue and the reason for the deviation from the shareholders' preferential rights are that the Company, in accordance with the press release published on 25 August